Expiry Date (miniseries)

Luca Mining's Upgrade Initiative at Campo Morado Gets Financial Boost with New Funding Package

Retrieved on:

Wednesday, December 6, 2023

The optimization program at Campo Morado is a major initiative and is expected to result in fundamental improvements in productivity, operational efficiency and cashflow.

Key Points:

The optimization program at Campo Morado is a major initiative and is expected to result in fundamental improvements in productivity, operational efficiency and cashflow.
Luca expects revenues from Campo Morado to increase by approximately 40% as a result of the optimization program.
Mike Struthers, CEO, commented, "This is a transformational initiative for Campo Morado.
I am confident that under this initiative we will be adding considerable value to the bottom line at Campo Morado, and hence to Luca as a whole."

Zoom Meetings & Google/Outlook Calendar Integration Accelerates Enterprise Contract Management Process

Retrieved on:

Tuesday, November 28, 2023

CLM, Synthetic media, ID, Generative, Expiry Date (miniseries), Calendar, Medical device

SUNNYVALE, Calif., Nov. 28, 2023 /PRNewswire-PRWeb/ -- SutiCLM latest features include key integrations, automated reminders, and more. Here are some of the key features: Zoom Integration Stakeholders can collaborate via Zoom meetings for contract reviews and approvals.

Key Points:

SutiCLM, a leading contract lifecycle management solution, has recently launched new features aimed at providing a flexible and collaborative contract management experience.
These additions have been thoughtfully developed to streamline the CLM process and deliver an improved user experience.
Here are some of the key features:
Stakeholders can collaborate via Zoom meetings for contract reviews and approvals.
Integrated Google/Outlook calendar keeps you track of upcoming events such as meetings, approvals, renewals, expiries, and more.

EQS-News: DEMIRE meets expectations with H1 2023 results

Retrieved on:

Monday, September 4, 2023

Tax, NAV, Expiry Date (miniseries), EBIT, Sale, LTV, Langen, FFO, EPRA, CEST, RTÉ Executive Board, ISIN, WALT, Lithium, Film industry, EUR

DEMIRE Deutsche Mittelstand Real Estate AG (ISIN: DE000A0XFSF0) has announced financial results for the first half of 2023 in line with management expectations.

Key Points:

DEMIRE Deutsche Mittelstand Real Estate AG (ISIN: DE000A0XFSF0) has announced financial results for the first half of 2023 in line with management expectations.
Rental income continues to rise, pre-tax FFO I slightly higher
During the first half, rental income rose by 3.4% to EUR 40.8 million (H1 2022: EUR 39.5 million), primarily due to rent indexation.
“DEMIRE made good progress in generating additional liquidity in the first half of 2023,” says Prof. Dr. Alexander Goepfert, Chief Executive Officer of DEMIRE.
The Executive Board of DEMIRE is pleased to invite all interested parties to participate in a conference call on 4th of September 2023, starting at 3:00 p.m. (CEST) during which the financial results for the first half of 2023 will be presented.

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Retrieved on:

Friday, July 14, 2023

Acceleration, Engagement letter, Indian stock exchange, CSE, Legislation, CDN, AGN, Expiry Date (miniseries), Warrant, Expiration date, Exercise, Letter, News, Regulation, Security (finance), Maxim

Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”).

Key Points:

Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”).
The Company will use the proceeds of the private placement for working capital purposes.
In connection with entering into the Engagement Letter, the Company may be obligated to issue up to an additional 200,000 Common Shares to Maxim in certain circumstances.
The Company may also be obligated to pay Maxim a success fee upon the consummation of a successful transaction.

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

Retrieved on:

Thursday, April 20, 2023

Upon completion of the Rights Offering and assuming all Rights are exercised, the Company will have 19,333,976 Shares outstanding, of which the Shares issued under the Rights Offering represent 50%, assuming no Warrants issued pursuant to the Rights Offering are exercised.

Key Points:

Upon completion of the Rights Offering and assuming all Rights are exercised, the Company will have 19,333,976 Shares outstanding, of which the Shares issued under the Rights Offering represent 50%, assuming no Warrants issued pursuant to the Rights Offering are exercised.
The Notice and the Rights DRS advice/subscription were mailed to Shareholders in the Eligible Jurisdictions as of the Record Date on or about April 5, 2023.
The Company expects to close the Rights Offering on or before May 3, 2023.
The Rights Agent will mail cheques representing the net proceeds, without interest, from such sales, to such ineligible Shareholders.

CME Group to Expand Bitcoin and Ether Options Expiries on May 22

Retrieved on:

Monday, April 17, 2023

New expiries for options on Bitcoin and Ether futures will be offered with Monday, Tuesday, Wednesday, Thursday, and Friday expirations.

Key Points:

New expiries for options on Bitcoin and Ether futures will be offered with Monday, Tuesday, Wednesday, Thursday, and Friday expirations.
Options on micro-sized Bitcoin and Ether futures will add Tuesday and Thursday expiries to their existing Monday, Wednesday and Friday contracts.
All of these new offerings will complement the existing monthly and quarterly expiries available across all Bitcoin and Ether options on futures contracts.
"CME Group continues to innovate and lead in the institutional crypto options on futures market," said Paul Eisma, Head of Options Trading at XBTO.

Algernon Pharmaceuticals Announces Launch of Rights Offering

Retrieved on:

Tuesday, March 21, 2023

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”).

Key Points:

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”).
Pricing of the Rights Offering is mandated by applicable Canadian securities law and the policies of the CSE which require the Company to offer existing Shareholders a significant discount to purchase new securities in order to provide a meaningful incentive to Shareholders to participate in the Rights Offering.
Upon completion of the Rights Offering and assuming all Rights are exercised, the Company will have 19,333,976 Shares outstanding, of which the Shares issued under the Rights Offering represent 50%, assuming no Warrants issued pursuant to the Rights Offering are exercised.
The proceeds of the Rights Offering are expected to be used for working capital and general corporate purposes and administrative expenses.

VERSES Announces Convertible Debenture Financing of up to C$5,000,000

Retrieved on:

Monday, February 27, 2023

Private placement, Debt, News, Official Committee of Equity Security Holders, Expiry Date (miniseries), Private, NEO, Placement, Equity (finance), Stock, Artificial intelligence, File, Finance Secretary (India), Convertible bond, Expiration date, Equity, Security (finance), Issuer, Warrant

Each Convertible Debenture will mature on the date that is 12 months from the date of issuance of the Convertible Debenture (the “Maturity Date”).

Key Points:

Each Convertible Debenture will mature on the date that is 12 months from the date of issuance of the Convertible Debenture (the “Maturity Date”).
On the Maturity Date, the outstanding principal amount of the Convertible Debentures (the “Principal Amount”) shall be repaid in cash.
For the purposes of this news release, “Equity Securities” means Shares of the Company or any securities convertible into or exercisable or exchangeable for Shares.
Each Convertible Debenture shall rank subordinate to all secured debt obligations of the Company.

Global Market for Medicines to Rise to $1.9 Trillion by 2027, says Report from IQVIA Institute

Retrieved on:

Wednesday, January 18, 2023

The total spending and global demand for medicines will increase over the next five years to approximately $1.9 trillion by 2027, according to a new report titled Global Use of Medicines 2023 – Outlook through 2027 from the IQVIA Institute for Human Data Science.

Key Points:

The total spending and global demand for medicines will increase over the next five years to approximately $1.9 trillion by 2027, according to a new report titled Global Use of Medicines 2023 – Outlook through 2027 from the IQVIA Institute for Human Data Science.
However, growth is projected to slow through 2027 and reach a total of more than 3.4 trillion doses, up about 8% from the 2022 level.
Spending and growth by regions: The global medicine market — using invoice price levels — is expected to grow at 3–6% CAGR through 2027 to about $1.9 trillion with diverging trends by region.
Growth in spending on specialty medicines: Specialty medicines will represent about 43% of global spending in 2027 and 56% of total spending in developed markets.

EQS-News: Altaley Mining Share Consolidation and Rights Offering

Retrieved on:

Sunday, December 18, 2022

Altaley Mining Corporation (the “Company” or “Altaley”) announces that the Company’s Board of Directors has approved a consolidation of the Company’s issued share capital on a ratio of one (1) new post-consolidated common share for every eight (8) old pre-consolidated common shares (the “Consolidation”).

Key Points:

Altaley Mining Corporation (the “Company” or “Altaley”) announces that the Company’s Board of Directors has approved a consolidation of the Company’s issued share capital on a ratio of one (1) new post-consolidated common share for every eight (8) old pre-consolidated common shares (the “Consolidation”).
The Company is also pleased to announce it will be making a rights offering (the “Rights Offering”) on a post-Consolidation basis in which holders of record of the Company’s post-Consolidation common shares (“Common Shares”), will receive rights (“Rights”) to subscribe for units (“Units”) of the Company.
The terms of the Rights Offering and the procedures for exercising Rights will be explained in the Notice and the Rights Offering Circular which will be issued after the Consolidation is completed.
Altaley Mining Corporation is a Canadian based mining company with two 100% owned Mexican gold, silver, and base metal mining projects.